Search results
Showing 601 to 615 of 667 results for kidney or kidneys or renal
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
include disease specific survival and toxicity, including the development of renal stones and hypercalcaemia. Any explanatory notes(if...
Anaemia management in people with chronic kidney disease (CG39)
This guideline has been updated and replaced by NICE guideline CG114.
Anaemia management in people with chronic kidney disease (CG114)
This guideline has been updated and replaced by NICE guideline NG8.
Chronic kidney disease in adults: assessment and management (CG182)
This guidance has been updated and replaced by NICE guideline NG203.
NICE has developed a medtech innovation briefing (MIB) on End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia .
COVID-19 rapid guideline: acute kidney injury in hospital (NG175)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia (CG157)
This guidance has been updated and replaced by NICE guideline NG203.
This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS212Show all sections
Sections for QS212
- Quality statements
- Quality statement 1: Recording BMI and waist-to-height ratio in adults
- Quality statement 2: Recording BMI in children and young people aged over 2 years
- Quality statement 3: Access to services for people with a learning disability
- Quality statement 4: Maintaining details of local and national overweight and obesity management interventions and services
- Quality statement 5: Providing information about local and national weight management interventions and services
- Quality statement 6: Wraparound care alongside medicines for weight management
- Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.